CinDome secures $40M for gastroparesis Phase II

CinDome announced on Thursday that it successfully secured $40 million in a series B extension, bringing the total capital raised in this round to $59 million. The newly acquired funds will be allocated to the ongoing Phase II envision3D study. This study is focused on evaluating CinDome's leading pharmaceutical candidate, deudomperidone (CIN-102), aimed at treating adults suffering from diabetic gastroparesis.

Deudomperidone is an innovative reformulation of domperidone, a small molecule traditionally used to combat nausea, vomiting, and gastroparesis in various countries. However, domperidone faces significant limitations as it is not approved in the United States due to its association with QT prolongation. This condition involves the heart muscle taking an irregularly long time to contract and relax, posing potential cardiac risks. Currently, there is no FDA-approved long-term treatment available for gastroparesis, creating an urgent need for effective and safer solutions.

CinDome’s deudomperidone is specifically designed to maintain the therapeutic benefits of domperidone while significantly minimizing its cardiac side effects. The Phase II envision3D study is pivotal in demonstrating the safety and efficacy of this new formulation. If successful, it could provide a much-needed treatment option for patients with diabetic gastroparesis.

The financing round was spearheaded by existing investors, including Perceptive Advisors and CinRx Pharma. These funds will not only support the continuation of the Phase II study but also prepare CinDome for the upcoming registrational trials of deudomperidone. This next phase is crucial for progressing towards potential regulatory approval and eventual commercialization.

In summary, CinDome’s recent financial boost is a significant step forward in their mission to develop and bring to market an effective treatment for diabetic gastroparesis. The successful advancement of deudomperidone could address a critical gap in medical care for patients suffering from this chronic condition.